EVTC:NYSEEvertec, Inc. Analysis
Data as of 2026-05-20 - not real-time
$24.30
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
EVTC is trading at $24.30, notably below its DCF‑derived fair value of $24.44 and the consensus 12‑month target of $31, implying roughly 27% upside. The stock sits beneath its 20‑day (26.86), 50‑day (28.01) and 200‑day (30.07) moving averages, with a bearish MACD and an RSI of 35, suggesting short‑term oversold conditions near the identified support of $21.82. Volume is trending upward, adding momentum to the price dip, and the imminent ex‑dividend date (May 11) may draw dividend‑seeking buyers, especially given a low 9.6% payout ratio and a 0.82% yield.
Fundamentally, EVTC delivers solid growth – revenue rose 8.4% YoY and forward EPS is projected to climb to $4.34, while the forward PE of 5.6 signals deep value. Margins are healthy (gross 50.3%, operating 17.9%) and cash flow is robust, supporting the dividend. Recent material news highlights a strategic partnership with Transbank in Chile and positive Q1 earnings driven by the Tecnobank acquisition, reinforcing the growth narrative. However, the company faces medium‑level regulatory and geographic risks inherent to fintech operations in Latin America, and a 30‑day volatility of 63.8% adds price swing potential.
Fundamentally, EVTC delivers solid growth – revenue rose 8.4% YoY and forward EPS is projected to climb to $4.34, while the forward PE of 5.6 signals deep value. Margins are healthy (gross 50.3%, operating 17.9%) and cash flow is robust, supporting the dividend. Recent material news highlights a strategic partnership with Transbank in Chile and positive Q1 earnings driven by the Tecnobank acquisition, reinforcing the growth narrative. However, the company faces medium‑level regulatory and geographic risks inherent to fintech operations in Latin America, and a 30‑day volatility of 63.8% adds price swing potential.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- RSI indicates oversold conditions
- Increasing volume suggests buying pressure
- Upcoming ex‑dividend date may boost demand
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued versus DCF and analyst target
- Strong earnings growth and low forward PE
- Strategic partnership in Chile expanding market reach
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustainable dividend with low payout ratio
- Robust ROE (~20%) and cash flow generation
- Diversified fintech platform and continued LATAM expansion
Key Metrics & Analysis
Financial Health
Revenue Growth8.40%
Profit Margin13.95%
P/E Ratio11.7
ROE20.17%
ROA5.39%
Debt/Equity148.53
P/B Ratio2.2
Op. Cash Flow$220.6M
Free Cash Flow$127.3M
Industry P/E38.0
Technical Analysis
TrendBearish
RSI35.9
Support$21.82
Resistance$30.85
MA 20$26.86
MA 50$28.01
MA 200$30.07
MACDBearish
VolumeIncreasing
Fear & Greed Index89.18
Valuation
Fair Value$24.44
Target Price$31.00
Upside/Downside27.57%
GradeUndervalued
TypeBlend
Dividend Yield0.82%
Risk Assessment
Beta0.71
Volatility63.79%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.